|
1
|
Hu L, Smith TF and Goldberger G: LFG: A
candidate apoptosis regulatory gene family. Apoptosis.
14:1255–1265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Somia NV, Schmitt MJ, Vetter DE, et al:
LFG: an anti-apoptotic gene that provides protection from
Fas-mediated cell death. Proc Natl Acad Sci USA. 96:12667–12672.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Beier CP, Wischhusen J, Gleichmann M, et
al: FasL (CD95L/APO-1L) resistance of neurons mediated by
phosphatidylinositol 3-kinase-Akt/protein kinase B-dependent
expression of lifeguard/neuronal membrane protein 35. J Neurosci.
25:6765–6774. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reimers K, Choi CY, Mau-Thek E, et al:
Sequence analysis shows that Lifeguard belongs to a new
evolutionarily conserved cytoprotective family. Int J Mol Med.
18:729–734. 2006.PubMed/NCBI
|
|
5
|
Bucan V, Reimers K, Choi CY, et al: The
anti-apoptotic protein lifeguard is expressed in breast cancer
cells and tissues. Cell Mol Biol Lett. 15:296–310. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bucan V, Adili MY, Choi CY, et al:
Transactivation of lifeguard (LFG) by Akt-/LEF-1 pathway in MCF-7
and MDA-MB 231 human breast cancer cells. Apoptosis. 15:814–821.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kondapaka SB, Singh SS, Dasmahapatra GP,
et al: Perifosine, a novel alkylphospholipid, inhibits protein
kinase B activation. Mol Cancer Ther. 2:1093–1103. 2003.PubMed/NCBI
|
|
8
|
Patel V, Lahusen T, Sy T, et al:
Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression
in squamous carcinoma cells through a p53-independent pathway,
leading to loss in cyclin-dependent kinase activity and cell cycle
arrest. Cancer Res. 62:1401–1409. 2002.
|
|
9
|
Gajate C and Mollinedo F: Edelfosine and
perifosine induce selective apoptosis in multiple myeloma by
recruitment of death receptors and downstream signaling molecules
into lipid rafts. Blood. 109:711–719. 2007. View Article : Google Scholar
|
|
10
|
Mollinedo F, de la Iglesia-Vicente J,
Gajate C, et al: In vitro and in vivo selective antitumor activity
of Edelfosine against mantle cell lymphoma and chronic lymphocytic
leukemia involving lipid rafts. Clin Cancer Res. 16:2046–2054.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Van der Luit AH, Vink SR, Klarenbeek JB,
et al: A new class of anticancer alkylphospholipids uses lipid
rafts as membrane gateways to induce apoptosis in lymphoma cells.
Mol Cancer Ther. 6:2337–2345. 2007.PubMed/NCBI
|
|
12
|
Bailey HH, Mahoney MR, Ettinger DS, et al:
Phase II study of daily oral perifosine in patients with advanced
soft tissue sarcoma. Cancer. 107:2462–2467. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Knowling M, Blackstein M, Tozer R, et al:
A phase II study of perifosine (D-21226) in patients with
previously untreated metastatic or locally advanced soft tissue
sarcoma: A National Cancer Institute of Canada Clinical Trials
Group trial. Invest New Drugs. 24:435–439. 2006. View Article : Google Scholar
|
|
14
|
Leighl NB, Dent S, Clemons M, et al: A
Phase II study of perifosine in advanced or metastatic breast
cancer. Breast Cancer Res Treat. 108:87–92. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Munoz-Martinez F, Torres C, Castanys S, et
al: The anti-tumor alkylphospholipid perifosine is internalized by
an ATP-dependent translocase activity across the plasma membrane of
human KB carcinoma cells. Biochim Biophys Acta. 1778:530–540. 2008.
View Article : Google Scholar
|
|
16
|
Vink SR, van der Luit AH, Klarenbeek JB,
et al: Lipid rafts and metabolic energy differentially determine
uptake of anti-cancer alkylphospholipids in lymphoma versus
carcinoma cells. Biochem Pharmacol. 74:1456–1465. 2007. View Article : Google Scholar
|
|
17
|
Mravljak J, Zeisig R and Pecar S:
Synthesis and biological evaluation of spin-labeled
alkylphospholipid analogs. J Med Chem. 48:6393–6399. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ruiter GA, Zerp SF, Bartelink H, et al:
Anti-cancer alkyl-lysophospholipids inhibit the
phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer
Drugs. 14:167–173. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vink SR, van Blitterswijk WJ, Schellens
JH, et al: Rationale and clinical application of alkylphospholipid
analogues in combination with radiotherapy. Cancer Treat Rev.
33:191–202. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Duggan BJ, Maxwell P, Kelly JD, et al: The
effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein
expression and apoptosis in human bladder transitional cell
carcinoma. J Urol. 166:1098–1105. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li F, Srinivasan A, Wang Y, et al:
Cell-specific induction of apoptosis by microinjection of
cytochrome c. Bcl-xL has activity independent of cytochrome c
release. J Biol Chem. 272:30299–30305. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Strasberg RM, Zangemeister-Wittke U and
Rieber M: p53- independent induction of apoptosis in human melanoma
cells by a bcl-2/bcl-xL bispecific antisense oligonucleotide. Clin
Cancer Res. 7:1446–1451. 2001.PubMed/NCBI
|
|
23
|
Tortora G, Caputo R, Damiano V, et al:
Combined blockade of protein kinase A and bcl-2 by antisense
strategy induces apoptosis and inhibits tumor growth and
angiogenesis. Clin Cancer Res. 7:2537–2544. 2001.
|
|
24
|
Zangemeister-Wittke U, Leech SH, Olie RA,
et al: A novel bispecific antisense oligonucleotide inhibiting both
bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor
cells. Clin Cancer Res. 6:2547–2555. 2000.
|
